AKTX - アカリ・セラピュ―ティクス （Akari Therapeutics Plc） アカリ・セラピュ―ティクスAKTXのチャート
AKTXの企業情報
| symbol | AKTx |
|---|---|
| 会社名 | Akari Therapeutics PLC （アカリ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Akari Therapeutics Plc formerly Celsus Therapeutics Plc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5) including paroxysmal nocturnal hemoglobinuria Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug Coversin a complement inhibitor acts on complement C5 preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases including disease states spanning hematology nephrology transplantation neurology and ophthalmology. アカリ・セラピュ―ティクスはイギリスのバイオ医薬品企業。臨床段階で、難病に対する治療薬の開発・商業化に取り組む。自己免疫の異常に起因するギラン・バレ―症候群に対するC5モノクロナ―ル抗体治療薬、また、発作性夜間ヘモグロビン尿症の治療薬の開発・商業化にも取り組む。同社パイプラインには「C5a」と「C5b-9」を含む。本社所在地は米国ニューヨーク。 Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. |
| 本社所在地 | 75/76 Wimpole Street London 10018 GBR |
| 代表者氏名 | Ray Prudo レイプルード |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +44 20-8004-0261 |
| 設立年月日 | 38261 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 17人 |
| url | www.akaritx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aktx |
| adr_tso | 15208377 |
| EBITDA | EBITDA（百万ドル） -31.69758 |
| 終値（lastsale） | 2.05 |
| 時価総額（marketcap） | 31177172.85 |
| 時価総額 | 時価総額（百万ドル） 32.19213 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 17.12219 |
| 当期純利益 | 当期純利益（百万ドル） -31.85552 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Akari Therapeutics PLC (ADR) revenues was not reported. Net loss applicable to common stockholders decreased 27% to $9.4M. Lower net loss reflects Research and development costs decrease of 37% to $6.1M (expense) Changes in fair value of option and warr increase of 5% to $2.8M (income) Interest income increase of 71% to $132K (income). |
AKTXのテクニカル分析
AKTXのニュース
Akari Therapeutics Plc: Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights 2023/05/01 12:10:00 Finanz Nachrichten
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two priority pipeline programs with potential to transform the comple…
Akari Therapeutics GAAP EPS of $0.00 2023/05/01 12:08:14 Seeking Alpha
Akari Therapeutics press release (AKTX): FY GAAP EPS of $0.00.At December 31, 2022, the Company had cash of approximately $13.2 million, compared to cash of approximately $9.4 million…
Akari Therapeutics Plc: Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement 2023/04/25 20:22:00 Finanz Nachrichten
NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory dise…
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement 2023/04/25 20:15:33 Investor Akaritx
NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has received notification from Nasdaq that Akari has been granted an
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement 2023/04/25 20:15:00 GlobeNewswire
NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has received notification from Nasdaq that Akari has been granted an additional 180-day period, or until October 23, 2023, to regain compliance with the Nasdaq minimum bid price requirement. Akari can regain compliance by maintaining a minimum closing bid price of $1.00 per share for a minimum of ten consecutive business days.
Akari Therapeutics Plc: Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting 2023/04/03 12:10:00 Finanz Nachrichten
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory dise…
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting 2023/04/03 12:00:00 GlobeNewswire
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the upcoming presentation of a case study, Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting , on Sunday, April 23 rd at 8:30 am (GMT+2). The poster presentation will take place at The European Society for Blood and Marrow Transplantation (EBMT) in Paris, France.
Malignant Pleural Effusion Market to Surpass Valuation of US$ 8.06 Billion by 2033 Owing to the Surging Prevalence of Malignant Pleural Effusion Disease Globally Says Future Market Insights, Inc. 2023/03/30 14:00:00 Accesswire
NEWARK, DE / ACCESSWIRE / March 30, 2023 / The global malignant pleural effusion market is anticipated to create lucrative growth opportunities over the forecast period by registering a CAGR of 6% from 2023 to 2033. The global market is expected to garner a market value of US$ 4.5 Billion in 2023 and is expected to accumulate a market value of US$ 8.06 Billion by 2033. According to the Future Market Insights historical analysis, the global malignant pleural effusion market registered a CAGR of 4% from 2018 to 2022. The growth of the market in the current evaluation period is expected to fuel due to the increasing incidence of pleural effusion disease and rising awareness of advancement in pleural effusion treatment with different types of techniques. Clinical examinations and procedures are rapidly carried out to diagnose the condition, which helps various medical professions in making additional and efficient decisions about medicine, testing, and recuperations. Such aforementioned factors are likely to accelerate market expansion throughout the projection period.
Akari Therapeutics to raise $4M in stock offering 2023/03/30 13:32:48 Seeking Alpha
Akari Therapeutics (AKTX) entered into definitive agreements with certain institutional investors and accredited investors which also includes board members, and President and…
Akari Therapeutics Plc: Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering 2023/03/30 13:22:00 Finanz Nachrichten
Offering includes 100% participation by Akari''s Board of Directors, including Akari President and CEO Rachelle JacquesOffering includes accredited investors who have not previously participatedDefi…
Unusual Ways to Leverage Your Investment:: Akari Therapeutics, Plc (NASDAQ:AKTX 4.82%), Neovasc Inc. (NASDAQ:NVCN 0.31%) 2023/02/25 13:11:30 Stock Equity
AKTX has seen its SMA50 which is now -23.37%. In looking the SMA 200 we see that the stock has seen a -52.99%. NVCN has seen its SMA50 which is … The post Unusual Ways to Leverage Your Investment:: Akari Therapeutics, Plc (NASDAQ:AKTX 4.82%), Neovasc Inc. (NASDAQ:NVCN 0.31%) appeared first on Stocks Equity .
Mind-boggling stocks: Cidara Therapeutics, Inc. (NASDAQ:CDTX), Akari Therapeutics, Plc (NASDAQ:AKTX) 2023/02/16 11:08:45 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Mind-boggling stocks: Cidara Therapeutics, Inc. (NASDAQ:CDTX), Akari Therapeutics, Plc (NASDAQ:AKTX) appeared first on Stocks Equity .
Akari Therapeutics Plc: Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) 2023/02/15 13:10:00 Finanz Nachrichten
Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024Composition of matter patent application filed on long-…
Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) 2023/02/15 13:00:00 GlobeNewswire
NEW YORK and LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced updates on progress in the pre-clinical development program for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
Akari Therapeutics Plc: Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults 2023/02/13 13:10:00 Finanz Nachrichten
Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is moving forward into design and planning for pivotal Part B of the Phase 3 cli…